Could This Drug Candidate Be a Blockbuster for Sanofi?
Published Apr 9, 2022 11:45AM EDT In March, Sanofi (NASDAQ: SNY) and its Sweden-based partner Sobi (OTC: SWTUY) announced positive phase 3 clinical trial results for efanesoctocog alfa, their jointly developed drug candidate for severe hemophilia A. The two companies expect to begin submitting applications for the drug's approval to…
bubmagApril 9, 2022